Saluda Medical, Inc Cdi 10:1 Us Person Prohibited Excluding Qib (ASX:SLD) Share Price & Analysis

Saluda Medical, Inc. (ASX: SLD) is a US-based, commercial-stage medical device company headquartered in Bloomington, Minnesota, with significant operational roots in Sydney, Australia. The company is dedicated to transforming the lives of patients suffering from chronic neurological conditions through its proprietary neuromodulation platform. Listed on the Australian Securities Exchange, Saluda focuses on the development and commercialization of advanced spinal cord stimulation technologies.

The company’s flagship product is the Evoke® System, the world’s first closed-loop spinal cord stimulation therapy designed to treat chronic neuropathic pain by sensing and measuring neural activation. Unlike traditional open-loop systems, Evoke utilizes Evoked Compound Action Potentials to automatically adjust stimulation levels millions of times per day in response to real-time neural signals. This technology is currently utilized in major markets including the United States, Australia, and Europe to provide personalized, data-driven pain management.

Saluda Medical maintains a strong market position by leveraging over 15 years of research and development to disrupt the global spinal cord stimulation industry. Its strategic focus involves expanding its commercial infrastructure, particularly in the United States, while advancing its sensing technology for broader neurological applications. By providing objective, physiological evidence of therapy efficacy, the company aims to establish a new standard of care for patients and clinicians worldwide.